CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis

Nature Medicine

Volumn 22, Issue 2, 2016, Pages 175-182

  Zhang, Ting ^a   Zhang, Yan ^a   Cui, Mingyao ^a   Jin, Li ^a   Wang, Yimei ^a   Lv, Fengxiang ^a   Liu, Yuli ^a   Zheng, Wen ^a   Shang, Haibao ^a   Zhang, Jun ^a   Zhang, Mao ^a   Wu, Hongkun ^a   Guo, Jiaojiao ^a   Zhang, Xiuqin ^a   Hu, Xinli ^a   Cao, Chun Mei ^a   Xiao, Rui Ping ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DOXORUBICIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN; RIP3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CARRIER PROTEIN; REACTIVE OXYGEN METABOLITE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, MOUSE;

ADULT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; INFLAMMATION; MOUSE; NECROPTOSIS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CELL SURVIVAL; CHEMICALLY INDUCED; COMPLICATION; CONFOCAL MICROSCOPY; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NECROSIS; PATHOLOGY; PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; SPRAGUE DAWLEY RAT; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL SURVIVAL; DOXORUBICIN; HEART FAILURE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NECROSIS; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES;

EID: 84957427310     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4017     Document Type: Article

References (55)

1. Kung, G., Konstantinidis, K. & Kitsis, R.N. Programmed necrosis, not apoptosis, in the heart. Circ. Res. 108, 1017-1036 (2011).
2. Whelan, R.S., Kaplinskiy, V. & Kitsis, R.N. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu. Rev. Physiol. 72, 19-44 (2010).
3. Cho, Y.S. et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112-1123 (2009).
4. He, S. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 137, 1100-1111 (2009).
5. Zhang, D.W. et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325, 332-336 (2009).
6. Kaiser, W.J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368-372 (2011).
7. Oberst, A. et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471, 363-367 (2011).
8. Upton, J.W., Kaiser, W.J. & Mocarski, E.S. Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe 7, 302-313 (2010).
9. Upton, J.W., Kaiser, W.J. & Mocarski, E.S. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11, 290-297 (2012).
10. Roychowdhury, S., McMullen, M.R., Pisano, S.G., Liu, X. & Nagy, L.E. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 57, 1773-1783 (2013).
11. Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213-227 (2012).
12. Welz, P.S. et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 477, 330-334 (2011).
13. Luedde, M. et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc. Res. 103, 206-216 (2014).
14. Zhao, J. et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl. Acad. Sci. USA 109, 5322-5327 (2012).
15. Humphries, F., Yang, S., Wang, B. & Moynagh, P.N. RIP kinases: key decision makers in cell death and innate immunity. Cell Death Differ. 22, 225-236 (2015).
16. Wu, J. et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res. 23, 994-1006 (2013).
17. 2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J. Clin. Invest. 117, 2431-2444 (2007).
18. Ferreira, A.L., Matsubara, L.S. & Matsubara, B.B. Anthracycline-induced cardiotoxicity. Cardiovasc. Hematol. Agents Med. Chem. 6, 278-281 (2008).
19. Singal, P.K. & Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905 (1998).
20. Yeh, E.T. & Bickford, C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53, 2231-2247 (2009).
21. Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727-741 (1999).
22. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229 (2004).
23. Degterev, A. et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4, 313-321 (2008).
24. Smith, C.C. et al. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc. Drugs Ther. 21, 227-233 (2007).
25. Lim, S.Y., Davidson, S.M., Mocanu, M.M., Yellon, D.M. & Smith, C.C. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc. Drugs Ther. 21, 467-469 (2007).
26. Oerlemans, M.I. et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res. Cardiol. 107, 270 (2012).
27. Wang, H. et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54, 133-146 (2014).
28. Vila-Petroff, M. et al. CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovasc. Res. 73, 689-698 (2007).
29. 2+/calmodulin-dependent protein kinase II δ mediates myocardial ischemia/reperfusion injury through nuclear factor-κB. Circ. Res. 112, 935-944 (2013).
30. Joiner, M.L. et al. CaMKII determines mitochondrial stress responses in heart. Nature 491, 269-273 (2012).
31. He, B.J. et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med. 17, 1610-1618 (2011).
32. Zhang, R. et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11, 409-417 (2005).
33. Zhu, W. et al. Activation of CaMKIIδC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J. Biol. Chem. 282, 10833-10839 (2007).
34. 2+/calmodulin kinase II. J. Clin. Invest. 111, 617-625 (2003).
35. Zhang, T. et al. The δC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res. 92, 912-919 (2003).
36. 2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 119, 1230-1240 (2009).
37. Erickson, J.R., He, B.J., Grumbach, I.M. & Anderson, M.E. CaMKII in the cardiovascular system: sensing redox states. Physiol. Rev. 91, 889-915 (2011).
38. Baines, C.P. et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434, 658-662 (2005).
39. Nakagawa, T. et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434, 652-658 (2005).
40. Brenner, C. & Moulin, M. Physiological roles of the permeability transition pore. Circ. Res. 111, 1237-1247 (2012).
41. Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163 (2007).
42. He, S., Liang, Y., Shao, F. & Wang, X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc. Natl. Acad. Sci. USA 108, 20054-20059 (2011).
43. Erickson, J.R. et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133, 462-474 (2008).
44. Li, Q. et al. Receptor interacting protein 3 suppresses vascular smooth muscle cell growth by inhibition of the phosphoinositide 3-kinase-Akt axis. J. Biol. Chem. 285, 9535-9544 (2010).
45. Sun, X. et al. RIP3, a novel apoptosis-inducing kinase. J. Biol. Chem. 274, 16871-16875 (1999).
46. Coupienne, I., Fettweis, G. & Piette, J. RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. Lasers Surg. Med. 43, 557-564 (2011).
47. Pazdernik, N.J., Donner, D.B., Goebl, M.G. & Harrington, M.A. Mouse receptor interacting protein 3 does not contain a caspase-recruiting or a death domain but induces apoptosis and activates NF-κB. Mol. Cell. Biol. 19, 6500-6508 (1999).
48. Moriwaki, K. & Chan, F.K. RIP3: a molecular switch for necrosis and inflammation. Genes Dev. 27, 1640-1649 (2013).
49. Montaigne, D. et al. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 11, 22-26 (2011).
50. Montaigne, D. et al. Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicol. Appl. Pharmacol. 244, 300-307 (2010).
51. Salas, M.A. et al. The signalling pathway of CaMKII-mediated apoptosis and necrosis in the ischemia/reperfusion injury. J. Mol. Cell. Cardiol. 48, 1298-1306 (2010).
52. Buja, L.M. Myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 14, 170-175 (2005).
53. Hausenloy, D.J. & Yellon, D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 123, 92-100 (2013).
54. Cao, C.M. et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121, 2565-2574 (2010).
55. Peng, W. et al. Cardioprotection by CaMKII-δB is mediated by phosphorylation of heat shock factor 1 and subsequent expression of inducible heat shock protein 70. Circ. Res. 106, 102-110 (2010).